series-c-plus
Stage
1
Investors
About
Castle Biosciences develops and commercializes genomic and proteomic diagnostic tests that provide risk stratification and clinical decision support for patients with skin cancers and other malignancies. Their commercially available assays (e.g., DecisionDx tests) are used by clinicians to inform prognosis and treatment planning.
Explore Castle Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.